federal health care law
The Obama administration’s surprise announcement Friday that it planned to give states broad leeway to pick the benefits offered under the offers yet another example of a gradualist approach to carrying out its signal domestic policy achievement.
health insurance
Facing vociferous Republican opposition, a looming Supreme Court decision on the constitutionality of the law and the practical challenges of overhauling the vast market for small businesses and individuals, federal officials are choosing to avoid some crucial choices until well after the 2012 elections. While critics accuse the administration of political expediency, the officials insist the decisions have been based on sound policy judgments.
In passing a good deal of the decision-making to states, the administration has guaranteed that Americans will continue to face a patchwork of state regulations that make coverage uneven and inefficient. People in Utah and Wyoming, for example, are likely to have more limited access to expensive services now mandated in states like Massachusetts and Maryland — at least until 2016, when a senior administration official said the federal government plans to determine which state-mandated benefits are not essential and must be either paid for by states or no longer mandated.
Read more at: http://www.nytimes.com/2011/12/21/health/policy/obamas-piecemeal-approach-to-health-law-in-states.html?ref=health
Source: The New York Times
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More